The registration of drug benefits such as Koselugo and Retevmo, which are currently under evaluation, is expected to be shortened by 30 days. This is because the NHIS and the HIRA have decided to shorten the benefit registration period for drugs used in life-threatening diseases. Koselugo and Retevmo are drugs licensed through the Ministry of Food and Drug Safety's rapid screening system and are considered life-threatening or significant treatments. This fact was revealed in the HIRA's written answer to the question asked by Rep. Seo Young-seok of the Democratic Party of Korea during the parliamentary audit on the 20th. Seo asked about "a specific plan to strengthen the information sharing and cooperation system among